Broad Institute

JULY 11, 2024

Treatment with mIDH1 blockers unearths these remnants, triggering an immune response against the tumor cells. IDH1 normally facilitates the activity of enzymes called demethylases, which remove chemical flags called methylation marks from DNA, allowing genes to be transcribed into RNA.

Treatment 72

Treatment Immune Response Drugs Virus 72

The Pharma Data

OCTOBER 25, 2020

German drugmaker CureVac said preclinical studies of its COVID-19 vaccine candidate, CVnCoV, showed the vaccination prompted a successful immune response. The messenger RNA-based vaccine, which is designed to block replication of the coronavirus, was shown to induce neutralizing antibodies and activate T-cells in hamsters and mice.

Vaccine 52

Vaccine Immune Response RNA Clinical Trials 52

Drug Target Review

DECEMBER 7, 2023

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. In bacteria , cGAS-like cyclases are central parts of the CBASS immune response.

RNA 59

RNA Immune Response DNA Molecular Biology 59

DrugBank

MARCH 12, 2025

Introduction Messenger RNA (mRNA) technology has emerged as one of the most significant medical breakthroughs. Once delivered into the body, the mRNA instructs cells to produce these antigens, which are then presented to the immune system. Another challenge is the potential for unintended immune responses.

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97

Drug Target Review

JUNE 6, 2023

Natural killer (NK) cells are another immune cell type that, as the name suggests, also have potent cell-killing activity, and have a well-known role in the anti-tumour immune response. In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

The Pharma Data

DECEMBER 14, 2020

Supported by promising phase 1 data, CureVac announced Monday that it has enrolled the first participant in the pivotal phase 2b/3 study of its messenger-RNA based coronavirus vaccine, CVnCoV. The company announced positive phase 1 trial results in November that demonstrated its candidate elicited immune responses and was well-tolerated.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection.

Vaccine 52

Vaccine Immune Response Virus RNA 52

Drug Target Review

FEBRUARY 7, 2024

We had built a machine learning classifier that has been trained to identify amino acid sequences that have the potential to mimic ‘host defense peptides’ from the human innate immune system. Such peptides play a critical role in the machinery for amplifying innate immune responses.

RNA 69

RNA Virus Immune Response Engineering 69

DrugBank

MAY 15, 2024

Another promising avenue is the use of technologies like RNA interference and gene editing, which allow scientists to turn off the production of certain proteins altogether. These methods could bypass the need to directly target these proteins with traditional drugs.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98

The Pharma Data

DECEMBER 8, 2020

. “In future analyses, with more data included as it becomes available, we will investigate differences in key subgroups such as older adults, various ethnicities, doses, timing of booster vaccines, and we will determine which immune responses equate to protection from infection or disease.” © 2020 HealthDay.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

MAY 17, 2021

Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. 14, 2020 ). The mRNA candidate is currently being assessed in a phase 1/2 study.

Vaccine 40

Vaccine Immune Response RNA Virus 40

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. CHENGDU, China , Feb. These findings give confidence that Clover’s COVID-19 vaccine candidates are suitable for further clinical development.”

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

SEPTEMBER 30, 2021

. “We used NanoSTING because the adjuvant for intranasal vaccination and single-cell RNA-sequencing to verify the nasal-associated lymphatic tissue as an inductive site upon vaccination. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.

Vaccine 52

Vaccine Disease Immune Response Virus 52

Dark Matter Blog

JULY 16, 2021

As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I wanted to use molecular biology to create drugs.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

LifeSciVC

JULY 1, 2024

The central dogma of molecular biology is that information generally (with few exceptions) flows from DNA to RNA to Protein. Build your social immunity. The adaptive immune response identifies and responds to highly specific antigens associated with infections and cancer. Remember life’s Central Dogma.

Science 92

Science Immune Response Molecular Biology RNA 92

The Pharma Data

JUNE 26, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JUNE 25, 2021

Phase 1 interim data reported in November 2020 showed that CVnCoV was generally well tolerated across all tested doses and induced strong antibody responses in addition to first indication of T cell activation. A pivotal Phase 2b/3, the HERALD study, with a 12µg dose of CVnCoV was initiated in December 2020. About CureVac.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. producing CD8+ T cell responses, which is thought to promote an anti-viral effect.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. Expected to enroll 415 participants; interim results expected in Q3 2021. In parallel, preclinical studies are underway to evaluate additional mRNA candidates against emerging SARS-CoV-2 variants.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.

Vaccine 52

Vaccine Trials Virus RNA 52

DrugBank

APRIL 24, 2025

Epigenetic changes are governed by chemical modifications such as DNA methylation, histone modifications, RNA-mediated processes, and all-controlling chromatin structure and gene accessibility. This dynamic regulatory network determines whether genes are turned on or off, ultimately influencing cellular identity and disease progression.

DNA 52

DNA Drugs Therapies Regulations 52

The Pharma Data

OCTOBER 25, 2020

The Phase 1 interim analysis showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. 26, 2020 11:00 UTC. CAMBRIDGE, Mass.–(

Vaccine 52

Vaccine Clinical Development RNA Clinical Trials 52

Drug Target Review

FEBRUARY 5, 2024

Using RNA sequencing to identify the proteins these cells secrete, they discovered that the macrophages from bone marrow responded differently on their own to interferon gamma, a protein produced by cells in response to infection, and lipopolysaccharide, a molecule found in some bacteria that stimulates the immune system.

Laboratories 59

Laboratories Immune Response RNA Regulations 59

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. ” In the same time period, mRNA vaccines were being deployed and immune responses to those vaccines were being studied.

Vaccine 52

Vaccine Virus Research Immune Response 52

Drug Target Review

APRIL 3, 2024

Our research demonstrated that GDF-15 acts as a versatile tool for tumours to inhibit the mounting of an effective antitumoral immune response at various steps of its process, including antigen presentation, immune cell activation, and their migration and infiltration into the tumour. in North America) in late 2017.

Science 105

Science Clinical Development Treatment DNA 105

The Pharma Data

JANUARY 13, 2021

The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan. More than 90% of participants mounted an immune response within a month, and all had levels of neutralizing antibodies by day 57. WEDNESDAY, Jan. vaccination efforts.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

The Pharma Data

JULY 6, 2021

Fitusiran is an investigational, subcutaneously administered small interference RNA therapy in development for the treatment of people with hemophilia A or B, with or without inhibitors and has the potential to transform treatment as it would be the only prophylactic therapy with as few as six injections per year.

Therapies 52

Therapies Pharmacokinetics Treatment RNA 52

Broad Institute

DECEMBER 6, 2023

The reference, called the Immune Dictionary , appears today in Nature. Using single-cell RNA sequencing to analyze gene expression in individual cells, the researchers have found how 86 major cytokines affect 17 immune cell types in mice. For many immune-mediated diseases, there's no cure or treatment.

Immune Response 138

Immune Response RNA Disease Medical Schools 138

Broad Institute

FEBRUARY 26, 2025

At the Broad, he decided to focus on myeloid cells, which make up to half of the cells in many brain tumors and can suppress the immune system, preventing immunotherapies from working well. To do this, the team used a different approach to single-cell analysis.

Immune Response 132

Immune Response Treatment RNA Clinical Trials 132

Broad Institute

OCTOBER 11, 2023

The drugs work by blocking a protein, PD-1 — which helps keep immune responses in check — and stimulating the immune system to attack tumors. The team studied the immune response to CRISPR and designed a new technology that they published in 2021 — a way of removing immune-triggering molecules from CRISPR-edited cells.

Research 137

Research Immune Response Clinical Trials Therapies 137

Broad Institute

JUNE 27, 2024

CRISPRoff silences the targeted gene by adding methyl groups, chemical tags that prevent the gene from being transcribed or read into RNA and so from being expressed as protein. ZFPs are also common in human cells, meaning they are less likely to trigger an immune response against themselves than the bacterial Cas9.

Disease 142

Disease Therapies Clinical Trials Engineering 142

Broad Institute

MAY 1, 2024

By Allessandra DiCorato May 1, 2024 Credit: Ricardo Job-Reese, Broad Communications The health benefits of exercise are well known but new research shows that the body’s response to exercise is more complex and far-reaching than previously thought. Whole-body analysis Conducting such a large and detailed study required a lot of planning.

RNA 143

RNA Regulations Immune Response Disease 143

Broad Institute

NOVEMBER 20, 2024

We now have a way of studying the whole organ, examining the effect of genetic variants and immune responses associated with diet, the microbiome, and gastrointestinal disease, and designing many other experiments.” Using single-cell RNA sequencing, the authors found that the changes occurred in three structural cell types.

Regulations 84

Regulations Immune Response Molecular Biology Disease 84

Drug Target Review

OCTOBER 2, 2024

RNA-based therapies, including mRNA and RNA interference (RNAi), are being explored to modulate gene expression in heart cells. While commonly used, AAVs have limitations, including immune reactions and difficulties with re-dosing due to pre-existing antibodies. Allogeneic cell therapies must avoid immune rejection.

Therapies 98

Therapies Disease RNA Engineering 98

Codon

APRIL 2, 2024

Like, if we start thinking about therapeutic circuits, how can we design the components in such a way that they are not going to cause an immune response? The RNA Exporter , which was developed by Felix Horns and others in my lab, is one example. The exported RNA could transfect just the target cell.

RNA 57

RNA Engineering Molecular Biology Synthetic Chemistry 57